Counseling Patients With Type 2 Diabetes and Insulin Resistance in the Outpatient Setting

Abstract

Get full access to this article

View all access options for this article.

References

1. American Diabetes Association . Consensus development conference on insulin resistance. Diabetes Care. 1998;21:310-314.

2. Rifkin H. Diabetic persons see RPhs 5 times more often than they visit physicians. Pharm Times. 1985:27.

3. National Institute of Diabetes and Digestive and Kidney Diseases . National diabetes statistics: general information and national estimates on diabetes in the United States, 2000. Available at: http://www.niddk.nih.gov/health/diabetes/pubs/dmstats/dmstats.htm. Accessed April 25, 2002.

4. Centers for Disease Control . Diabetes: a serious public health problem. At a Glance 2002. Available at: http//vwww.cdc.gov/diabetes/pubs/glance.htm. Accessed April 25, 2002.

5. O'Keefe JH Jr , Miles JM , Harris WH , et al. Improving the adverse cardiovascular prognosis of type 2 diabetes. Mayo Clin Proc. 1999;74:171-180.

6. Harris Ml , ed. Diabetes in America. Bethesda, Md; National Institutes of Health; 1995. NIH publication 95-1468.

7. Turner NC , Clapham JC . Insulin resistance, impaired glucose tolerance, and non-insulin-dependent diabetes, pathologic mechanisms and treatment: current status and therapeutic possibilities. Prog Drug Res. 1998;51:36-94.

8. Campbell RK , Bennett J. Assessing diabetes patients' healthcare needs. Diabetes Educ. 2002;28: 40-44, 49-50.

9. American Diabetes Association . Screening for diabetes. Diabetes Care. 2002;25(suppl 1): S21-S24.

10.

10. Bailey CJ , Insulin resistance and antidiabetic drugs. Biochem Pharmacol. 1999;58:1511-1520.

11.

11. Tuomilehto J , Lindstrom J , Eriksson JG , et al. Prevention of type 2 diabetes mellitus by change in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;44:1343-1350.

12.

12. KnowlerWC , Barrett-Connor E , Fowler SE , et al, for the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.

13.

13. Wallberg-Henriksson H. Exercise in the management of non-insulindependent diabetes mellitus. Sports Med. 1998;25:25-35.

14.

14. Haire-Joshu D , Glasgow RE , Tibbs TL . Smoking and diabetes [technical review]. Diabetes Care. 1999; 22:1887-1898.

15.

15. Chiasson J-L , Josse RG , Gomis R , et al, for the STOP-NIDDM Trial Research Group. Acarbose can prevent the progression of impaired glucose tolerance to type 2 diabetes mellitus: results of a randomized clinical trial: the STOP-NIDDM Trial. Lancet. 2002;359:2002-2007.

16.

16. Buchanan TA , Xiang AH , Peters RK , et al. Preservation of beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 2002;51:2796-2803.

17.

17. American Diabetes Association and National Institute of Diabetes, Digestive and Kidney Diseases . The prevention or delay of type 2 diabetes. Diabetes Care. 2002;25:742-749.

18.

18. Goldstein D , Little R , Wiedmeyer HM , et al. Glycated hemoglobin: methodologies and clinical applications. Clin Chem. 1986;32(suppl):B64-B70.

19.

19. American Diabetes Association . Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2002; 25(suppl 1):S33-S49.

20.

20. Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.

21.

21. United Kingdom Prospective Diabetes Study Group . Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;353:837-853.

22.

22. American Diabetes Association . Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care. 2002; 25(suppl 1):S28-S32.

23.

23. Gerich JE . Oral hypoglycemic agents. N Engl J Med. 1989;321: 1231-1245.

24.

24. Turner RC , Cull CA , Frighi V , et al, for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylureas, metformin, or insulin, in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281: 2005-2012.

25.

25. Lebovitz HE , Kreider M , Freed MI . Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care. 2002;25: 815-821.

26.

26. Forman LM , Simmons DA , Diamond RH . Hepatic failure in a patient taking rosiglitazone. Ann Intern Med. 2000;132:118-121.

27.

27. Al-Salman J , Arjomand H , Kemp DG , et al. Hepatocellular injury in a patient taking rosiglitazone: a case report. Ann Intern Med. 2000;132:121-124.

28.

28. Gouda HE , Khan A , Schwartz J , et al. Liver failure in a patient treated with long-term rosiglitazone therapy. Am J Med. 2001; 111:584-585.

29.

29. Ravinuthala RS , Nori U. Rosiglitazone toxicity. Ann Intern Med. 2000; 133:658-658.

30.

30. May LD , Lefkowitch JH , Kram MT , et al. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann Intern Med. 2002;136:449-452.

31.

31. Maeda K. Hepatocellular injury in a patient receiving pioglitazone. Ann Intern Med. 2001 135:306-306.

32.

32. Chase MP , Yarze JC . Pioglitazone-associated fulminant hepatic failure [letter]. Am J Gastroenterol. 2002;97:502-503.

33.

33. Actos® (pioglitazone hydrochloride) [package insert]. Lincolnshire, III & Indianapolis, Ind: Takeda Pharmaceuticals America & Eli Lilly; January 2002.

34.

34. Avandia® (rosiglitazone maleate) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; February 2001.

35.

35. Aronoff S , Rosenblatt S , Braithewaite S , et al, and the Pioglitazone 001 Study Group . Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized, placebo-controlled, dose-response study. Diabetes Care. 2000;23:1605-1611.

36.

36. Phillips LS , Grunberger G , Miller E , et al. Onceand twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care. 2001; 24:308-315.

37.

37. Kipnes MS , Krosnick A , Rendell MS , et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. AmJ Med. 2001;111: 10-17.

38.

38. Einhom D , Rendell M , Rosensweig J , et al, and the Pioglitazone 027 Study Group . Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther. 2000;22: 1395-1409.

39.

39. Rosenstock J , Einhom D , Hershon K , et al, and the Pioglitazone 014 Study Group . Efficacy and safety of pioglitazone in type 2 diabetes: a randomized, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract. 2002;56:251-257.

40.

40. FonsecaV , Rosenstock J , Patwardhan R , et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 2000;283: 1695-1702.

41.

41. Wolffenbuttel BH , Gomis R , Squatrito S , et al. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabetic Med. 2000;17:40-47.

42.

42. Boyle PJ , King AB , Olansky L , et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther. 2002;24: 378-396.

43.

43. Glucophage® (metformin hydrochloride) [package insert]. Princeton, NJ: Bristol-Myers Squibb; June 2001.

44.

44. Hermann LS , Schersten B , Bitzen PO , et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: a doubleblind controlled study. Diabetes Care. 1994;17: 1100-1109.

45.

45. Stumvoll M , Nurjhan N , Perriello G , et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:550-554.

46.

46. The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: the MCE system of intensive diabetes self-management- 2002. Endocr Pract. 2002; 8(suppl 1):40-82.

47.

47. Centers for Disease Control. CDC's diabetes program-statistics: diabetes surveillance, 1999. Chapter 10, figure 10.1. Available at: http://www.cdc.gov/diabetes/statistics/survl99/chapl0/figl.htm. Accessed March 4, 2002.

48.

48. Morbidity and Mortality Weekly Report (MMWR) . Recommendations and reports . Strategies for reducing morbidity and mortality from diabetes through health-care system interventions and diabetes self-management education in community settings. Sep 28, 2001/50(RR16): 1-15. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5O16a1/htm. Accessed March 4, 2002.

49.

49. Tankova T , Dakovska G , Koev D. Education of diabetic patients: a one year experience. Patient Educ Couns. 2001;43:139-145.

50.

50. Donnan PT , MacDonald TM , Morris AD . Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabetic Med. 2002;19: 279-284.

51.

51. ZoellerJ . Getting paid for diabetes disease management: a guide for pharmacists. American Druggist. 1998; Apr(suppl):2-7.

52.

52. Anonymous . Diabetes pathway slashes length of stay by 26%. Hosp Care Manage. 1999;7:8-8,13-13.